Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival
Authors
Keywords
Breast cancer, Trastuzumab, Cardiotoxicity, Survival, Outcomes research
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 146, Issue 2, Pages 411-419
Publisher
Springer Nature
Online
2014-06-20
DOI
10.1007/s10549-014-3029-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy
- (2014) Rachel A. Freedman et al. BREAST CANCER RESEARCH AND TREATMENT
- Risk of cardiovascular adverse events from trastuzumab (Herceptin®) in elderly persons with breast cancer: a population-based study
- (2014) H.-T. Tsai et al. BREAST CANCER RESEARCH AND TREATMENT
- Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
- (2014) Ghideon Ezaz et al. Journal of the American Heart Association
- Trastuzumab-related cardiac events in the treatment of early breast cancer
- (2013) Georgeta Fried et al. BREAST CANCER RESEARCH AND TREATMENT
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Improved targeting of cancer care for older patients: A systematic review of the utility of comprehensive geriatric assessment
- (2013) Aliya Ramjaun et al. Journal of Geriatric Oncology
- Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines
- (2012) G. Curigliano et al. ANNALS OF ONCOLOGY
- Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study
- (2012) Grzegorz Piotrowski et al. Archives of Medical Science
- Immortal Time Bias: A Frequently Unrecognized Threat to Validity in the Evaluation of Postoperative Radiotherapy
- (2012) Henry S. Park et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2012) Edward H. Romond et al. JOURNAL OF CLINICAL ONCOLOGY
- Incidence of Heart Failure or Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer
- (2012) Jersey Chen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Sensitivity of Medicare Claims Data for Measuring Use of Standard Multiagent Chemotherapy Regimens
- (2012) Elizabeth B. Lamont et al. MEDICAL CARE
- Administration of Angiotensin-Converting Enzyme Inhibitors and -Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?
- (2012) S. Oliva et al. ONCOLOGIST
- Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network
- (2011) R M Webster et al. BRITISH JOURNAL OF CANCER
- Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
- (2011) Luigi Tarantini et al. JOURNAL OF CARDIAC FAILURE
- Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery
- (2010) L.J. Murray et al. BREAST
- Polypharmacy in Older Adults with Cancer
- (2010) R. J. Maggiore et al. ONCOLOGIST
- Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
- (2009) Marc Spielmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Immortal Time Bias in Pharmacoepidemiology
- (2007) S. Suissa AMERICAN JOURNAL OF EPIDEMIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now